SCHEMBL3377016

SCHEMBL3377016

CS(=O)(=O)Nc1ccc(-c2ccc(Cl)c(F)c2)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 7/20 0.64
HSD17B1 P14061 1/20 0.47
HSD17B2 P37059 1/20 0.47
CDC7 O00311 1/20 0.46
PLK4 O00444 1/20 0.46
DAPK3 O43293 1/20 0.46
DYRK3 O43781 1/20 0.46
JAK2 O60674 1/20 0.46
ROCK2 O75116 1/20 0.46
PRKD3 O94806 1/20 0.46
MAP4K4 O95819 1/20 0.46
CDK1 P06493 1/20 0.46
ROS1 P08922 1/20 0.46
CDK2 P24941 1/20 0.46
MARK3 P27448 1/20 0.46
TYK2 P29597 1/20 0.46
KDR P35968 1/20 0.46
CLK2 P49760 1/20 0.46
JAK3 P52333 1/20 0.46
MAPK12 P53778 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3377263 0.87 KIF11 (0.67) KIF11HSD17B1HSD17B2CDC7PLK4
SCHEMBL3932771 0.86 KIF11 (0.50) KIF11KCNH2GRIN1GRIN2BKDM4E
SCHEMBL3377400 0.85 KIF11 (0.48) KIF11PTGS2HPGDSCN9A
SCHEMBL3376954 0.85 KIF11 (0.48) KIF11KCNH2GRIN1GRIN2BPTGS1
SCHEMBL3374918 0.85 KIF11 (0.69) KIF11HSD17B1HSD17B2CDC7PLK4
SCHEMBL4659822 0.82 KIF11 (0.66) KIF11HSD17B1HSD17B2CDC7PLK4
SCHEMBL3375785 0.80 KIF11 (0.59) KIF11SCN9A
SCHEMBL3376946 0.80 CYP17A1 (0.51) KIF11PTGS2ALDH1A1LMNAHTT
SCHEMBL3379148 0.80 KDM1A (0.55) KIF11PTGS1PTGS2KDM4EALDH1A1
SCHEMBL31041151 0.78 KIF11 (0.79) KIF11HSD17B1HSD17B2CDC7PLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8389500-B2 Fused heterocyclic compounds as ion channel modulators GILEAD SCIENCES, INC. (US) 2013-03-05 US claimed
WO-2010056527-A2 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD PALO ALTO, INC. (US) 2010-05-20 WO claimed
US-20100113449-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD PALO ALTO, INC. (US) 2010-05-06 US claimed
US-8389500-B2 Fused heterocyclic compounds as ion channel modulators GILEAD SCIENCES, INC. (US) 2013-03-05 US disclosed
WO-2010056527-A2 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD PALO ALTO, INC. (US) 2010-05-20 WO disclosed
US-20100113449-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD PALO ALTO, INC. (US) 2010-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113449-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS KCNJ2, HCN4, KCNH2 KIF11 3561/4885HSD17B1 2180/4885HSD17B2 2286/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.